dr. S.F. Oosting

E-mail:
s.oosting umcg.nl

Research

Publications
  1. Hypocalcemia induced by tyrosine kinase inhibitors: targeted treatment with 'untargeted' side effects

    Berends, A. M. A., van der Horst-Schrivers, A. N. A., Oosting, S. F., Kapiteijn, E. W., de Groot, J. W. B. & Links, T. P., 14-Feb-2020, In : ACTA ONCOLOGICA. p. 1-4 4 p.

    Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

  2. Results from a randomised phase I/II trial evaluating the safety and antitumour activity of anti-PD-1 (MEDI0680)/anti-PD-L1 (durvalumab) vs anti-PD-1 (nivolumab) alone in metastatic clear cell renal cell carcinoma (ccRCC)

    Voss, M. H., Azad, A. A., Hansen, A. R., Gray, J. E., Welsh, S. J., Achour, I., Hu, H., Lewis, L., Walcott, F. L. & Oosting, S. F., Oct-2019, In : Annals of Oncology. 30, 1 p.

    Research output: Contribution to journalMeeting AbstractAcademic

  3. Safety and efficacy of atezolizumab (atezo) in patients (pts) with autoimmune disease (AID): Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma

    Loriot, Y., Sternberg, C. N., Castellano Gauna, D., Dumez, H., Huddart, R., Vianna, K. M., Alonso Gordoa, T., Skoneczna, I. A., Fay, A., Sacco, C. S. P., Nole, F., Massari, F., Brasiuniene, B., Maroto, P., Oosting, S. F., Fear, S., Di Nucci, F., De Ducla, S. & Choy, E., Oct-2019, In : Annals of Oncology. 30, p. 368-369 2 p.

    Research output: Contribution to journalMeeting AbstractAcademic

  4. Lesion detection by [Zr-89]Zr-DFO-girentuximab and [F-18] FDG-PET in patients with newly diagnosed metastatic renal cell carcinoma

    Verhoeff, S., van Es, S. C., Boon, E., van Helden, E., Angus, L., Elias, S. G., Oosting, S. F., Aarntzen, E. H., Brouwers, A. H., Kwee, T. C., Heskamp, S., Hoekstra, O. S., Verheul, H., Zwezerijnen, G. J. C., van Oordt, C. M. D. H., van der Veldt, A. A. M., de Vries, E. G. E., Boerman, O. C., van der Graaf, W. T. A., Oyen, W. J. G. & van Herpen, C. M. L., Oct-2019, In : European Journal of Nuclear Medicine and Molecular Imaging. 46, SUPPL 1, p. S67 1 p.

    Research output: Contribution to journalMeeting AbstractAcademic

View all (85) »

Activities
  1. European Society for Medical Oncology (ESMO) , Lugano , Switzerland. (External organisation)

    S. F. Oosting (Member)
    2019

    Activity: MembershipMembership of committeeAcademic

  2. European Society for Medical Oncology (ESMO) , Lugano , Switzerland. (External organisation)

    S. F. Oosting (Member)
    2019

    Activity: MembershipMembership of committeeAcademic

  3. European Society for Medical Oncology (ESMO) , Lugano , Switzerland. (External organisation)

    S. F. Oosting (Member)
    20182019

    Activity: MembershipMembership of committeeAcademic

View all (7) »

View graph of relations

ID: 393538